Shopping Cart
- Remove All
- Your shopping cart is currently empty
Briakinumab (ABT-874) is a monoclonal antibody targeting IL-12, used in the study of psoriasis, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $228 | In Stock | |
5 mg | $562 | In Stock | |
10 mg | $845 | In Stock | |
25 mg | $1,250 | In Stock | |
50 mg | $1,680 | In Stock |
Description | Briakinumab (ABT-874) is a monoclonal antibody targeting IL-12, used in the study of psoriasis, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. |
Targets&IC50 | FcRn:0.27 μM (Kd) |
In vitro | The affinity of Briakinumab to FcRn was Kd = 0.27μM. [1] |
In vivo | Administering Briakinumab to FcRn knockout (KO) mice via a tail vein, the Briakinumab treated group showed faster clearance compared to wild-type mice. [1] |
Alias | J 695, BSF415977, BSF 415977, ABT-874, ABT874, A-796874.0 |
Cas No. | 339308-60-0 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.